Johnson & Johnson Backs Out of Bavarian Nordic HPV and HBV Vaccine Collaborations

May 9, 2022

Johnson & Johnson

J&J has announced that it is pulling out of hepatitis B virus (HBV) and human papillomavirus (HPV) vaccine development partnerships with Bavarian Nordic. The companies, which began their collaborations in 2014 with Ebola vaccine development, will continue their work on other projects. This includes the ongoing development of its Ebola and HIV vaccines.

According to Phil Taylor of PharmaPhorum,” The initial agreements were expanded in 2017 to add in HIV and HBV vaccine candidates, with another $10 million upfront payment, and equity investment of $33 million and up to $836 million in milestones. Under the terms of the alliances, Bavarian Nordic was tasked with designing, producing and delivering MVA-BN candidates, with Janssen responsible for R&D.”

To read more, click here.

(Source: PharmaPhorum, May 9th, 2022)

Share This Story!